- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04591951
Family Navigation to Improve ADHD Treatment Adherence for Minority Children (I2-ART)
A Family Navigator Intervention to Improve ADHD- Related Treatment Adherence (I2-ART) for Minority Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The proposed project involves three phases consistent with the ORBIT model:
Phase 1a (9 months): The Parent Empowerment Program (PEP) developed by Dr. Hoagwood (consultant), has been tested in a diverse population of children and adults with mental illnesses, such as anxiety and depression, and has been shown to increase family empowerment, access to mental health services, and self-efficacy skills. However, PEP has not focused on ADHD care. The investigators will use the PEP program as I2-ART's foundation but specifically tailor the intervention to improve adherence to ADHD treatments using findings from the empirical literature regarding facilitators and barriers to adherence for African American (AA) and Latinx (Lx) youth with ADHD and their families. The investigators will gather feedback from the focus groups in Phase 1a to make adaptations to I2-ART and determine the most effective ways to deploy I2-ART, which will be needed to implement the intervention during Phase 1b. Focus groups participants (N=24) will include 6 clinicians (e.g., psychologists, general pediatricians, and developmental pediatricians), 6 experienced family navigators from prior PI and co-mentors' studies (3 Lx, 3 AA), 6 caregivers who are experienced with ADHD treatment for their child (3 Lx, 3 AA), and 6 caregivers of treatment-naïve children with ADHD (3 Lx, 3 AA). Eight focus groups will be conducted using the well-established Morgan & Krueger approach (e.g., group size of 3-6 participants). Separate focus groups will be conducted for each stakeholder group and for Spanish-speaking participants, including at least one focus group for clinicians, two for family navigators (1 Lx, 1 AA), and four for caregivers (2 Lx, 2 AA). First, the investigators will gather information from caregivers of children with ADHD who are experienced with ADHD treatment (Parent Focus Group 1) regarding their receptivity to collaboration with a family navigator as well as the most effective ways to introduce family navigator/caregiver dyads to each other and support their relationship. Then, the investigators will conduct focus groups with clinicians to obtain their perspective on needed PEP adaptations to address barriers to ADHD treatment adherence and how to identify patients within their clinical practices who may benefit from working with a family navigator. Next, the investigators will hold focus groups with family navigators to understand preferences for intervention delivery, including their feedback on the use of ADHD shared decision-making tools and animated videos to overview session key points with minority families. Feedback from all focus groups will be used to modify the I2-ART treatment manual and implementation plans, which will subsequently be reviewed by focus groups of caregivers of treatment-naïve children with ADHD (Parent Focus Group 2) for additional modifications. Throughout the focus groups, the investigators will use feedback to ensure I2-ART's cultural appropriateness. All focus groups will be facilitated by the PI and co-mentors experienced with focus groups (Drs. Modi, Crosby and Jacquez), and will last 1-2 hours. All sessions will be audio-/video-recorded, field notes composed, and sessions transcribed verbatim. The primary deliverable is the design and content for the I2-ART intervention, including a draft treatment manual.
Phase 1b (12 months): Four family navigators (2 Lx, 2 AA) will receive I2-ART training, and then will implement I2-ART with 2-3 culturally matched caregivers each (n=8-12). Feasibility, acceptability, and satisfaction with I2-ART will be assessed after intervention implementation. The investigators will make modifications to the I2-ART treatment manual based upon family navigator and caregiver feedback. Based on the PEP model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). The family navigators' I2-ART training will include these areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting (session 1), at least three monthly in-person meetings (sessions 2, 3, and 4), and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad. Family navigators will meet weekly with research staff for supervision and case review. Family navigators and caregivers will complete questionnaires at baseline (B), after session 1 (Time 1), after session 2 (Time 2), after session 3 (Time 3), and immediately post-intervention (Time 4), and 3 months post-intervention (Time 5). In addition, the PI will interview the family navigators and caregivers to gain a more detailed understanding of their I2-ART experiences. After Phase 1b completion, the investigators will modify I2-ART as needed.
Phase 2 (24 months): Using a 2-wave approach, the investigators will evaluate the preliminary effectiveness of the revised I2-ART intervention, compared to a "usual care" control condition, on ADHD treatment adherence (e.g., initiation, implementation, and discontinuation of ADHD medication and/or behavioral treatment) in minority children (Lx, AA) with ADHD. Four family navigators (2 Lx, 2 AA) will implement the I2-ART treatment manual in 2 waves:
Wave 1 (12 months): Thirty caregivers (15 Lx, 15 AA) will be randomly assigned to the intervention group (n=20; 10Lx, 10AA) or "usual care" control group (n=10; 5Lx, 5AA). A research liaison at each recruitment site will request caregivers' permission for research staff to contact potential participants. Research staff will phone these families, and then meet face-to-face with those interested in study participation for informed consent. After enrollment, primary caregivers from both groups will meet with research staff to complete demographic and baseline measures (B). Then, for the intervention group, the family navigators will implement I2-ART for 3 months (including a 2-hour face-to-face meeting with the caregivers, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails). Family navigators will also meet weekly with research staff for supervision and case review. Caregivers in the control group will receive "usual care." In addition to completing the baseline surveys, family navigators and caregivers from both the intervention and control groups will complete questionnaires at Time 4 (immediately post-I2-ART for the intervention group) and Time 5 (3-months post-I2-ART for the intervention group).
Wave 2 (12 months): Thirty caregivers (15 Lx, 15 AA) will be randomly assigned to the intervention group (n=20; 10Lx, 10AA) or "usual care" control group (n=10; 5Lx, 5AA), and will use the same procedures as described for Wave 1.
Treatment fidelity will be measured through self-report from family navigators and caregivers, as well as through research staff assessment. For self-report, family navigators and caregivers will complete questionnaires to indicate whether they implemented/received identified intervention components. In addition, the investigators will audio record all family navigator/caregiver sessions (n=48 for Phase 1b, n=240 for Phase 2); then, the investigators will code 10% of the Phase 1b sessions (n=4) and 20% of the Phase 2 sessions (n=48) for fidelity. As with prior mentors' projects (Drs. Epstein and Froehlich),4,5 two independent coders (PI and research coordinator) will be trained and calibrated on the coding scheme and Noldus® software until reaching 90% reliability. The investigators will double code half of the coded sessions and will compute intraclass correlation coefficients to determine reliability of the fidelity coding. In addition, to ensure uniformity of intervention delivery, the investigators will develop an animated video using Vyond (an animated software tool) to provide an overview of core concepts and key points for each family navigator/caregiver session. This animated video overview of each session's contents will be viewed jointly by the family navigator and caregiver, and used as a springboard for discussion.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Clinicians.
Inclusion Criteria:
- Currently providing care for children with ADHD as psychologists, general pediatricians, or developmental pediatricians.
- > 18 years old.
- Any race/ethnicity.
Exclusion Criteria:
* Unable to read/speak either English or Spanish.
Family navigators.
Inclusion Criteria:
- Having experience working as family navigator and/or community health worker.
- Latinx (Lx) or African American (AA).
- > 18 years old.
Exclusion Criteria:
* Unable to read/speak either English or Spanish.
- Caregivers.
Inclusion Criteria:
- Phase 1a: current or former caregiver of a child with ADHD, with and without experience with ADHD treatment.
- Phases 1b and 2: current caregiver of a child (aged 7-11 years) with ADHD who is ADHD treatment-naïve at study enrollment.
- Lx or AA.
- > 18 years old.
Exclusion Criteria:
* Unable to read/speak either English or Spanish.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: I2-ART Group
I2-ART intervention will be modeled based on the Parent Empowerment Program model.
It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals).
I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options.
The caregivers in the I2-ART group will receive the intervention for 3 months.
The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
|
Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals).
The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each).
Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
|
|
Placebo Comparator: Control Group
The caregivers in the control group will receive "usual care."
|
Care as usual
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Intervention Sessions
Time Frame: 3 months after intervention, up to 6 months
|
The family navigators will record the number of sessions attended by caregivers.
|
3 months after intervention, up to 6 months
|
|
Length of Intervention Sessions
Time Frame: 3 months after intervention, up to 6 months
|
The family navigators will record the length of sessions attended by caregivers.
|
3 months after intervention, up to 6 months
|
|
Satisfaction with Intervention Immediately after Intervention
Time Frame: Immediately after intervention, up to 3 months
|
This is a 7-item Likert scale questionnaire that elicits caregivers' and family navigators' opinions regarding the format, content, length, and convenience of the intervention.
Answers ranged from Strongly Agree to Strongly Disagree.
Higher score means better outcome (satisfaction).
|
Immediately after intervention, up to 3 months
|
|
Satisfaction with Intervention 3 months after Intervention
Time Frame: 3 months after intervention, up to 6 months
|
This is a 7-item Likert scale questionnaire that elicits caregivers' and family navigators' opinions regarding the format, content, length, and convenience of the intervention.
Answers ranged from Strongly Agree to Strongly Disagree.
Higher score means better outcome (satisfaction).
|
3 months after intervention, up to 6 months
|
|
System Usability Scale Immediately after Intervention
Time Frame: Immediately after intervention, up to 3 months
|
The System Usability Scale is a 10-item Likert scale questionnaire that elicits family navigators' global views of the I2-ART treatment manual's usability.
Answers ranged from Strongly Agree to Strongly Disagree.
Higher score means better outcome (satisfaction).
|
Immediately after intervention, up to 3 months
|
|
System Usability Scale 3 months after Intervention
Time Frame: 3 months after intervention, up to 6 months
|
The System Usability Scale is a 10-item Likert scale questionnaire that elicits family navigators' global views of the I2-ART treatment manual's usability.
Answers ranged from Strongly Agree to Strongly Disagree.
Higher score means better usability (outcome).
|
3 months after intervention, up to 6 months
|
|
Family Navigator Activities Checklist
Time Frame: 3 months after intervention, up to 6 months
|
This 27-item checklist will document family navigator-caregiver activities, including emotional support, action planning, information provision, advocacy, and skill development.
Higher score means better outcomes (more activities covered by family navigators).
|
3 months after intervention, up to 6 months
|
|
Implementation Questionnaire
Time Frame: 3 months after intervention, up to 6 months
|
The implementation questionnaire will include 10 items recording information about treatment fidelity, time needed for the intervention, enrollment rate, reasons for declining participation, representativeness of the sample, facilitators/barriers to delivering the I2-ART intervention, facilitators/barriers for sustaining intervention after study completion, feedback regarding intervention.
Higher score means better implementation (outcome).
|
3 months after intervention, up to 6 months
|
|
Change in Services Use in Children and Adolescents from Immediately after Intervention to 3 months after Intervention
Time Frame: Immediately after intervention (up to 3 months) and 3 months after intervention (up to 6 months)
|
This structured interview assesses use of services for mental health and related issues (e.g., medication and/or behavior therapy).
|
Immediately after intervention (up to 3 months) and 3 months after intervention (up to 6 months)
|
|
ADHD medication initiation immediately after intervention
Time Frame: Immediately after intervention, up to 3 months
|
We will obtain data regarding ADHD medication initiation based on Prescription Drug Monitoring Program records and medical chart review.
|
Immediately after intervention, up to 3 months
|
|
ADHD medication initiation 3 months after intervention
Time Frame: 3 months after intervention, up to 6 months
|
We will obtain data regarding ADHD medication initiation based on Prescription Drug Monitoring Program records and medical chart review.
|
3 months after intervention, up to 6 months
|
|
Percent of days covered with ADHD medication immediately after intervention
Time Frame: Immediately after intervention, up to 3 months
|
We will obtain data regarding percent of days covered with medication once initiated based on Prescription Drug Monitoring Program records.
|
Immediately after intervention, up to 3 months
|
|
Percent of days covered with ADHD medication 3 months after intervention
Time Frame: 3 months after intervention, up to 6 months
|
We will obtain data regarding percent of days covered with medication once initiated based on Prescription Drug Monitoring Program records.
|
3 months after intervention, up to 6 months
|
|
Discontinuation of ADHD medication immediately after intervention
Time Frame: Immediately after intervention, up to 3 months
|
We will obtain data regarding discontinuation of medication once initiated based on Prescription Drug Monitoring Program records and medical chart review.
|
Immediately after intervention, up to 3 months
|
|
Discontinuation of ADHD medication 3 months after intervention
Time Frame: 3 months after intervention, up to 6 months
|
We will obtain data regarding discontinuation of medication once initiated based on Prescription Drug Monitoring Program records and medical chart review.
|
3 months after intervention, up to 6 months
|
|
Behavior Therapy Initiation immediately after intervention
Time Frame: Immediately after intervention, up to 3 months
|
Through medical chart review, we will obtain data regarding initiation of behavior therapy when recommended by clinician.
|
Immediately after intervention, up to 3 months
|
|
Behavior Therapy Initiation 3 months after intervention
Time Frame: 3 months after intervention, up to 6 months
|
Through medical chart review, we will obtain data regarding initiation of behavior therapy when recommended by clinician.
|
3 months after intervention, up to 6 months
|
|
Number of Behavior Therapy Visits immediately after intervention
Time Frame: Immediately after intervention, up to 3 months
|
We will obtain data regarding the number of behavior therapy visits attended by family through medical chart review.
|
Immediately after intervention, up to 3 months
|
|
Number of Behavior Therapy Visits 3 months after intervention
Time Frame: 3 months after intervention, up to 6 months
|
We will obtain data regarding the number of behavior therapy visits attended by family through medical chart review.
|
3 months after intervention, up to 6 months
|
|
Behavior Therapy Disengagement immediately after intervention
Time Frame: Immediately after intervention, up to 3 months
|
We will obtain data regarding behavior therapy disengagement through medical chart review.
|
Immediately after intervention, up to 3 months
|
|
Behavior Therapy Disengagement 3 months after intervention
Time Frame: 3 months after intervention, up to 6 months
|
We will obtain data regarding behavior therapy disengagement through medical chart review.
|
3 months after intervention, up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Vanderbilt ADHD Parent Report Scale Scores from baseline to 3 months after intervention
Time Frame: Baseline and 3 months after intervention
|
The Vanderbilt ADHD Parent Report Scale is a 25-item scale that assess ADHD symptoms, including 9 attention items and 9 hyperactivity/impulsive items.
Answers ranged from (0) Never to (3) Very Often.
Summary scores for the 2 ADHD symptom domains are created by summing the 9 inattention and the 9 hyperactivity/impulsivity items.
|
Baseline and 3 months after intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Working Alliance Inventory
Time Frame: Baseline, after first session (up to 1 week), after intervention session (up to 1 month), after third session (up to 2 months), immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
The Working Alliance Inventory is a 12-item measure of a family's perceived agreement with their healthcare provider on the goals/tasks of treatment and the extent to which they have a strong personal bond with their provider.
Respondents rate their responses on a scale of 1 (strongly disagree) to 5 (strongly agree).
Item scores are summed, giving a range from 12-60, with higher scores indicating a better family-provider alliance.
|
Baseline, after first session (up to 1 week), after intervention session (up to 1 month), after third session (up to 2 months), immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
|
Family Empowerment Scale
Time Frame: Baseline, after first session (up to 1 week), after intervention session (up to 1 month), after third session (up to 2 months), immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
The Family Empowerment Scale is a 12-item scale that assess perceptions and attitudes about family navigator and caregiver roles/responsibilities within their local service systems and their ability to advocate on behalf of their children.
Items are scored on a 5-point likert type scale from 1 (Never) to 5 (Very often).
The FES assesses three domains, Work (e.g.
"I know what to do when problems arise with the families with whom I work"), Children's Services (e.g., "I make sure that professionals understand caregivers' opinions about what services their children need"), and Community (e.g.
"I feel I can have a part in improving services for children in my community").
|
Baseline, after first session (up to 1 week), after intervention session (up to 1 month), after third session (up to 2 months), immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
|
Collaborative Skills Questionnaire
Time Frame: Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
The Collaborative Skills Questionnaire is a 36-item scale examining key knowledge and skills development related to training modules.
It includes six subscales, one for each I2-ART training manual module: (1) Listening, Engagement, and Boundary Settings Skills, (2) Group Management, (3) Priority Setting, (4) Specific Disorders and Their Treatment, (5) Mental Health Services, and (6) School Options.
Questions include, "I can talk to parents about our mutual responsibilities in the working relationship" and "I am aware of barriers that parents may face in seeking help for their children and know how to help them overcome those barriers."
|
Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
|
Vanderbilt Mental Health Services Efficacy
Time Frame: Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
This 25-item scale examines the degree to which family navigators and caregivers feel effective in accessing mental health services.
Items are scored on a five-point scale from 1 (strongly disagree) to 5 (strongly agree).
Typical items include, "I believe that I can help parents access and use effectively mental health services for their children" and "My skills in dealing with mental health services will help me to empower parents to change things that might be wrong with their child's treatment."
|
Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
|
Brief Illness Perceptions Questionnaire
Time Frame: Baseline, after first session (up to 1 week), after intervention session (up to 1 month), after third session (up to 2 months), immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
This 11-item scale is designed to assess a parent's representation of ADHD (e.g.
expected time course, consequences, causes, etc.).
It has good test-retest reliability as well as concurrent and predictive validity.
All of the items, except the causal scale, are rated using a 0 to 10 response scale.
For the causal scale, parents list the three most important causal factors in their child's ADHD/ADD, and responses are grouped into categories (genetic, environmental, behavioral, dietary, etc.) for analysis.
|
Baseline, after first session (up to 1 week), after intervention session (up to 1 month), after third session (up to 2 months), immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
|
Beliefs about Medicines Questionnaire
Time Frame: Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
The validated 25-item Beliefs about Medicines Questionnaire has two domains, Specific and General.
The BMQ-Specific comprises two scales: 1) Necessity (parent beliefs about the necessity of prescribed medication) and 2) Concerns (parent concerns about potential adverse consequences of using medication).
The BMQ-General comprises two scales: 1) Overuse (parent beliefs about overuse of medicine by doctors) and 2) Harm (parent belief about the intrinsic harmfulness of medicine).
For all items on all scales, respondents indicate their degree of agreement with each individual statement on a 5-point Likert-type scale (e.g., 1=strongly disagree to 5=strongly agree).
Scores obtained for the individual items within each scale are summed to give a scale score.
Mean scores are also calculated for each scale (range of 1 to 5).
In addition, a Necessity/Concerns Differential (NCD) is calculated by subtracting the mean Concerns scale score from the mean Necessity scale score (range of -4 to 4).
|
Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
|
Decisional Conflict Scale
Time Frame: Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
This 16-item validated measure elicits the parent's preference for treatment options and parent-perceived sources of decisional conflict about their preferred option.
The scale produces a total score with five subscales: 1) informed; 2) values clarity; 3) support; 4) uncertainty; 5) effective decision.
Lower scores are desirable, with a range from 0-100.
|
Baseline, immediately after intervention (up to 3 months), 3 months after intervention (up to 6 months)
|
|
Participants' Age
Time Frame: Baseline
|
Through the Background History Form, the investigators will collect the family navigators' and caregivers' age.
|
Baseline
|
|
Participants' Race and Ethnicity
Time Frame: Baseline
|
The Background History Form will collect family navigators' and caregivers' race and ethnicity.
|
Baseline
|
|
Participants' Employment Status
Time Frame: Baseline
|
The Background History Form will collect family navigators' and caregivers' employment status.
|
Baseline
|
|
Caregivers' Income
Time Frame: Baseline
|
The Background History Form will collect caregivers' household income.
|
Baseline
|
|
Caregivers' Educational Level
Time Frame: Baseline
|
The Background History Form will collect caregivers' educational level.
|
Baseline
|
|
Caregivers' Marital Status
Time Frame: Baseline
|
The Background History Form will collect caregivers' marital status.
|
Baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kelly Kamimura-Nishimura, MD, Children's Hospital Medical Center, Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1K23MH125138-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
King's College LondonActive, not recruitingAttention-Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder SymptomsUnited Kingdom
-
Cingulate TherapeuticsSuspendedPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Cingulate TherapeuticsPremier Research Group plcCompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Central South UniversityRecruitingAttention-Deficit/Hyperactivity DisorderChina
-
Qbtech ABEnrolling by invitationAttention Deficit Disorder With Hyperactivity (ADHD) | Attention Deficit Disorder (ADD)United States
-
Universidade do Sul de Santa CatarinaAssociação Brasileira de Cannabis MedicinalRecruitingAttention-Deficit/Hyperactivity Disorder (ADHD)Brazil
-
Nanjing Medical UniversityRecruitingAdult Attention Deficit Hyperactivity DisorderChina
-
Children's Hospital Medical Center, CincinnatiPatient-Centered Outcomes Research Institute; Children's Hospital of Philadelphia and other collaboratorsNot yet recruitingAttention-Deficit/Hyperactivity Disorder (ADHD)United States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAttention Deficit Disorder With HyperactivityUnited States
Clinical Trials on I2-ART
-
University of Kansas Medical CenterNational Cancer Institute (NCI)CompletedColorectal CancerUnited States
-
Cairo UniversityNot yet recruiting
-
Laboratoires NEGMAUnknown
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingNasal Obstruction | Empty Nose SyndromeUnited States
-
King Abdullah University HospitalCompletedPTSD - Post Traumatic Stress DisorderJordan
-
Albany Medical CollegeRecruitingPregnancy Complications | Pregnancy | Satisfaction, Patient | Hospitalization | Hospital EnvironmentUnited States
-
Uppsala County Council, SwedenUppsala University; Region Gävleborg; Västmanland County Council, Sweden; Uppsala...CompletedMedication ReviewSweden
-
Florida State UniversityCompleted
-
Asahi Kasei Pharma CorporationCompletedPostoperative Stage II/III Colon CancerJapan
-
University of DerbyCompletedPerinatal Mental HealthUnited Kingdom